

Henry P Parkman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9529118/publications.pdf>

Version: 2024-02-01

270
papers

17,682
citations

10986

71
h-index

15732

125
g-index

287
all docs

287
docs citations

287
times ranked

6531
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Guideline: Management of Gastroparesis. American Journal of Gastroenterology, 2013, 108, 18-37.	0.4	904
2	American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology, 2004, 127, 1592-1622.	1.3	644
3	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. American Journal of Gastroenterology, 2008, 103, 753-763.	0.4	588
4	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology, 2016, 150, 1481-1491.	1.3	400
5	Cellular Changes in Diabetic and Idiopathic Gastroparesis. Gastroenterology, 2011, 140, 1575-1585.e8.	1.3	368
6	Botulinum Toxin A for the Treatment of Delayed Gastric Emptying. American Journal of Gastroenterology, 2008, 103, 416-423.	0.4	318
7	Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology, 1998, 115, 747-762.	1.3	317
8	Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterology and Motility, 2006, 18, 263-283.	3.0	316
9	Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterology and Motility, 2011, 23, 8-23.	3.0	305
10	Investigation of Colonic and Whole-Gut Transit With Wireless Motility Capsule and Radiopaque Markers in Constipation. Clinical Gastroenterology and Hepatology, 2009, 7, 537-544.	4.4	297
11	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Journal of Nuclear Medicine Technology, 2008, 36, 44-54.	0.8	295
12	Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Alimentary Pharmacology and Therapeutics, 2008, 27, 186-196.	3.7	293
13	Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterology and Motility, 2003, 15, 89-102.	3.0	286
14	Clinical Features of Idiopathic Gastroparesis Vary With Sex, Body Mass, Symptom Onset, Delay in Gastric Emptying, and Gastroparesis Severity. Gastroenterology, 2011, 140, 101-115.e10.	1.3	281
15	Gastroparesis-Related Hospitalizations in the United States: Trends, Characteristics, and Outcomes, 1995-2004. American Journal of Gastroenterology, 2008, 103, 313-322.	0.4	267
16	Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterology and Motility, 2008, 20, 311-319.	3.0	261
17	Gastroparesis. Nature Reviews Disease Primers, 2018, 4, 41.	30.5	235
18	AGA technical review on nausea and vomiting. Gastroenterology, 2001, 120, 263-286.	1.3	220

#	ARTICLE	IF	CITATIONS
19	Characteristics of Patients With Chronic Unexplained Nausea and Vomiting and Normal Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 567-576.e4.	4.4	212
20	Wireless Capsule Motility: Comparison of the SmartPill® GI Monitoring System with Scintigraphy for Measuring Whole Gut Transit. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2167-2174.	2.3	202
21	Treatment of Idiopathic Gastroparesis With Injection of Botulinum Toxin Into The Pyloric Sphincter Muscle. <i>American Journal of Gastroenterology</i> , 2002, 97, 1653-1660.	0.4	194
22	American Gastroenterological Association medical position statement: Diagnosis and treatment of gastroparesis. <i>Gastroenterology</i> , 2004, 127, 1589-1591.	1.3	191
23	Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 833-839.	1.0	190
24	Gastric Electrical Stimulation With Enterra Therapy Improves Symptoms From Diabetic Gastroparesis in a Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 947-954.e1.	4.4	186
25	Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. <i>Neurogastroenterology and Motility</i> , 2010, 22, 874.	3.0	185
26	Effect of gastric acid suppressants on human gastric motility. <i>Gut</i> , 1998, 42, 243-250.	12.1	183
27	Similarities and Differences Between Diabetic and Idiopathic Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 1056-1064.	4.4	174
28	Cyclic vomiting syndrome in adults. <i>Neurogastroenterology and Motility</i> , 2008, 20, 269-284.	3.0	172
29	Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. <i>Neurogastroenterology and Motility</i> , 2010, 22, 113-133.	3.0	171
30	Advances in the diagnosis and classification of gastric and intestinal motility disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 291-308.	17.8	168
31	Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. <i>Neurogastroenterology and Motility</i> , 2012, 24, 531.	3.0	164
32	Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. <i>Digestive Diseases and Sciences</i> , 2001, 46, 24-29.	2.3	160
33	Whole Gut Transit Scintigraphy in The Clinical Evaluation of Patients With Upper and Lower Gastrointestinal Symptoms. <i>American Journal of Gastroenterology</i> , 2000, 95, 2838-2847.	0.4	152
34	Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2640.	7.4	149
35	Dietary Intake and Nutritional Deficiencies in Patients With Diabetic or Idiopathic Gastroparesis. <i>Gastroenterology</i> , 2011, 141, 486-498.e7.	1.3	148
36	Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features. <i>Gastroenterology</i> , 2021, 160, 2006-2017.	1.3	141

#	ARTICLE	IF	CITATIONS
37	Clinical and translational advances in esophageal squamous cell carcinoma. <i>Advances in Cancer Research</i> , 2019, 144, 95-135.	5.0	140
38	Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. <i>Digestive Diseases and Sciences</i> , 1997, 42, 10-18.	2.3	126
39	Predictive Factors for Clinical Improvement with Enterra Gastric Electric Stimulation Treatment for Refractory Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2072-2078.	2.3	126
40	The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 313-322.	3.7	123
41	Regional Postprandial Differences in pH Within the Stomach and Gastroesophageal Junction. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2276-2285.	2.3	120
42	Assessing pyloric sphincter pathophysiology using EndoFLIP in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2015, 27, 524-531.	3.0	120
43	Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. <i>Gastroenterology</i> , 2018, 154, 65-76.e11.	1.3	117
44	Electrogastrography and Gastric Emptying Scintigraphy Are Complementary for Assessment of Dyspepsia. <i>Journal of Clinical Gastroenterology</i> , 1997, 24, 214-219.	2.2	112
45	Development and content validity of a gastroparesis cardinal symptom index daily diary. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 670-680.	3.7	110
46	Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis. <i>Gastroenterology</i> , 2015, 149, 1762-1774.e4.	1.3	110
47	Gastric Per Oral Endoscopic Myotomy (G-POEM) for the Treatment of Refractory Gastroparesis: Early Experience. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2405-2412.	2.3	108
48	Ultrastructural differences between diabetic and idiopathic gastroparesis. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1573-1581.	3.6	104
49	Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. <i>Digestive Diseases and Sciences</i> , 2003, 48, 488-497.	2.3	103
50	Psychological Dysfunction Is Associated With Symptom Severity but Not Disease Etiology or Degree of Gastric Retention in Patients With Gastroparesis. <i>American Journal of Gastroenterology</i> , 2010, 105, 2357-2367.	0.4	103
51	Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. <i>Neurogastroenterology and Motility</i> , 2013, 25, 427.	3.0	103
52	Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation. <i>Gastroenterology</i> , 2016, 150, 1292-1304.e2.	1.3	103
53	Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index – Daily Diary (GCSI – DD). <i>Neurogastroenterology and Motility</i> , 2012, 24, 456-463.	3.0	101
54	Abdominal Pain Is a Frequent Symptom of Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 676-681.	4.4	100

#	ARTICLE	IF	CITATIONS
55	Cholinergic effects on human gastric motility. <i>Gut</i> , 1999, 45, 346-354.	12.1	96
56	Gastric Neuromuscular Pathology in Gastroparesis: Analysis of Full-Thickness Antral Biopsies. <i>Digestive Diseases and Sciences</i> , 2010, 55, 359-370.	2.3	96
57	Altered Expression of Ano1 Variants in Human Diabetic Gastroparesis. <i>Journal of Biological Chemistry</i> , 2011, 286, 13393-13403.	3.4	95
58	Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2013, 25, 815.	3.0	95
59	Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2639-45.	2.3	94
60	Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. <i>Neurogastroenterology and Motility</i> , 2010, 22, 527-33, e117.	3.0	91
61	Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. <i>American Journal of Gastroenterology</i> , 1997, 92, 968-75.	0.4	91
62	The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 879-893.	2.3	85
63	Gastric Emptying of Solids and Liquids for Evaluation for Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1138-1146.	2.3	84
64	Association of low numbers of ^{CD}206 ⁺ positive cells with loss of ^{ICC} in the gastric body of patients with diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1275-1284.	3.0	83
65	Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2025-2031.	2.3	81
66	Simultaneous measurement of gastric emptying with a simple muffin meal using [13C]octanoate breath test and scintigraphy in normal subjects and patients with dyspeptic symptoms. <i>Digestive Diseases and Sciences</i> , 2002, 47, 1657-1663.	2.3	80
67	Gastrointestinal motility and dysmotility: an update on techniques available for evaluation. <i>American Journal of Gastroenterology</i> , 1995, 90, 869-92.	0.4	79
68	Influence of age, gender, and menstrual cycle on the normal electrogastrogram. <i>American Journal of Gastroenterology</i> , 1996, 91, 127-33.	0.4	79
69	Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 1-7.	2.2	78
70	Diabetic and idiopathic gastroparesis is associated with loss of ^{CD}206 ⁺ positive macrophages in the gastric antrum. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13018.	3.0	77
71	Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1256-1263.e1.	4.4	75
72	Neurotrophin-3 Improves Functional Constipation. <i>American Journal of Gastroenterology</i> , 2003, 98, 1338-1347.	0.4	74

#	ARTICLE	IF	CITATIONS
73	Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release ¹ . <i>Neurogastroenterology and Motility</i> , 2005, 17, 348-354.	3.0	74
74	High-resolution solid-state manometry of the antropyloroduodenal region. <i>Neurogastroenterology and Motility</i> , 2007, 19, 188-195.	3.0	72
75	Gastric Emptying Scintigraphy. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 209-215.	2.2	71
76	Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G1107-G1114.	3.4	70
77	Regional gastric emptying abnormalities in functional dyspepsia and gastro-oesophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2006, 18, 894-904.	3.0	68
78	Mirtazapine for symptom control in refractory gastroparesis. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 1035-1041.	4.3	67
79	Gastric Electric Stimulation for Refractory Gastroparesis: A Prospective Analysis of 151 Patients at a Single Center. <i>Digestive Diseases and Sciences</i> , 2016, 61, 168-175.	2.3	66
80	Optimal evaluation of patients with nonobstructive esophageal dysphagia. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1355-1368.	2.3	65
81	Effect of dietary fat and food consistency on gastroparesis symptoms in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2015, 27, 501-508.	3.0	65
82	Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13196.	3.0	65
83	Symptoms of Gastroparesis: Use of the Gastroparesis Cardinal Symptom Index in Symptomatic Patients Referred for Gastric Emptying Scintigraphy. <i>Digestion</i> , 2008, 78, 144-151.	2.3	64
84	Chronic nausea and vomiting: evaluation and treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 647-659.	0.4	64
85	Clinical Response and Side Effects of Metoclopramide. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 494-503.	2.2	61
86	Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1902-1914.	3.0	61
87	Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1285-1294.e1.	4.4	60
88	Nausea and vomiting in diabetic and idiopathic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2012, 24, 217.	3.0	59
89	Tests of Gastric Neuromuscular Function. <i>Gastroenterology</i> , 2009, 136, 1526-1543.	1.3	57
90	Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12981.	3.0	57

#	ARTICLE	IF	CITATIONS
91	Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G291-G297.	3.4	56
92	Abnormal Ghrelin and Pancreatic Polypeptide Responses in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1339-1346.	2.3	54
93	Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects. <i>Digestive Diseases and Sciences</i> , 2011, 56, 115-124.	2.3	54
94	Foods Provoking and Alleviating Symptoms in Gastroparesis: Patient Experiences. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1052-1058.	2.3	53
95	Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1770-1779.e2.	4.4	53
96	Bloating in Gastroparesis: Severity, Impact, and Associated Factors. <i>American Journal of Gastroenterology</i> , 2011, 106, 1492-1502.	0.4	52
97	Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3545-3551.	2.3	52
98	Simultaneous assessment of gastric accommodation and emptying: studies with liquid and solid meals. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1155-60.	5.0	52
99	Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1001-1015.	3.0	51
100	Multichannel Electrogastrography (EGG) in Normal Subjects: A Multicenter Study. <i>Digestive Diseases and Sciences</i> , 2004, 49, 594-601.	2.3	50
101	Assessment of symptoms during gastric emptying scintigraphy to correlate symptoms to delayed gastric emptying. <i>Neurogastroenterology and Motility</i> , 2010, 22, 539-45.	3.0	50
102	The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2004-2013.	5.0	50
103	Small Intestinal Bacterial Overgrowth in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 645-652.	2.3	50
104	Idiopathic Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 59-68.	2.2	49
105	Avoidant/restrictive food intake disorder symptoms are frequent in patients presenting for symptoms of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13931.	3.0	49
106	Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2021, 160, 76-87.e4.	1.3	49
107	Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. <i>Neurogastroenterology and Motility</i> , 2014, 26, 521-528.	3.0	48
108	Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. <i>Journal of Nuclear Medicine</i> , 2018, 59, 691-697.	5.0	48

#	ARTICLE	IF	CITATIONS
109	REVIEW: The Use of Botulinum Toxin for the Treatment of Gastrointestinal Motility Disorders. <i>Digestive Diseases and Sciences</i> , 2004, 49, 165-175.	2.3	43
110	Ethnic, Racial, and Sex Differences in Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1489-1499.e8.	4.4	43
111	Chronic intestinal pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 3-11.	0.8	42
112	Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 650-655.	2.4	42
113	Diagnosis and management of esophageal achalasia. <i>BMJ, The</i> , 2016, 354, i2785.	6.0	42
114	Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2242-2255.	2.3	42
115	Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotonergic stimulation. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G612-G619.	3.4	41
116	Granisetron Transdermal System Improves Refractory Nausea and Vomiting in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1231-1234.	2.3	41
117	Use of a High Caloric Liquid Meal as an Alternative to a Solid Meal for Gastric Emptying Scintigraphy. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2001-2006.	2.3	40
118	Chronic opioids in gastroparesis: Relationship with gastrointestinal symptoms, healthcare utilization and employment. <i>World Journal of Gastroenterology</i> , 2017, 23, 7310-7320.	3.3	40
119	Metoclopramide for the treatment of diabetic gastroparesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 711-721.	3.0	39
120	Assessment of Gastric Emptying and Small-Bowel Motility: Scintigraphy, Breath Tests, Manometry, and SmartPill. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009, 19, 49-55.	1.4	38
121	Advanced Training in Neurogastroenterology and Gastrointestinal Motility. <i>Gastroenterology</i> , 2015, 148, 881-885.	1.3	38
122	Characteristics of Nausea and Its Effects on Quality of Life in Diabetic and Idiopathic Gastroparesis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 317-321.	2.2	37
123	Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: Relationship with etiology, gastric emptying, and symptom severity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13810.	3.0	37
124	Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, G1384-G1391.	3.4	36
125	Effectiveness of gastric electrical stimulation in gastroparesis: Results from a large prospectively collected database of national gastroparesis registries. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13714.	3.0	36
126	Delayed Gastric Emptying Associates With Diabetic Complications in Diabetic Patients With Symptoms of Gastroparesis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1778-1794.	0.4	34

#	ARTICLE	IF	CITATIONS
127	Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. <i>American Journal of Physiology - Renal Physiology</i> , 1995, 269, G418-G426.	3.4	33
128	Factors Contributing to Hospitalization for Gastroparesis Exacerbations. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2404-2409.	2.3	33
129	Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. <i>PLoS ONE</i> , 2018, 13, e0194759.	2.5	33
130	Migraine and Gastroparesis From a Gastroenterologist's Perspective. <i>Headache</i> , 2013, 53, 4-10.	3.9	32
131	Multichannel Electrogastrography (EGG) in Symptomatic Patients: A Single Center Study. <i>American Journal of Gastroenterology</i> , 2004, 99, 478-485.	0.4	31
132	The Influence of Race on Symptom Severity and Quality of Life in Gastroparesis. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 757-761.	2.2	31
133	Use of simultaneous high-resolution endoluminal sonography (HRES) and manometry to characterize high pressure zone of distal esophagus. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1660-1666.	2.3	29
134	Achalasia Presenting After Operative and Nonoperative Trauma. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1818-1821.	2.3	28
135	Effect of meal size and test duration on gastric emptying and gastric myoelectrical activity as determined with simultaneous [¹³ C]octanoate breath test and electrogastrography in normal subjects using a muffin meal. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2643-2650.	2.3	26
136	Gastric neuromuscular histology in patients with refractory gastroparesis: Relationships to etiology, gastric emptying, and response to gastric electric stimulation. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13068.	3.0	26
137	Reflux Symptoms in Gastroparesis. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 428-438.	2.2	26
138	Erythromycin inhibits rabbit pyloric smooth muscle through neuronal motilin receptors. <i>Gastroenterology</i> , 1996, 111, 682-690.	1.3	25
139	Variation of symptoms during the menstrual cycle in female patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2011, 23, 625-e254.	3.0	25
140	Outcomes of surgical intervention for refractory gastroparesis: a systematic review. <i>Journal of Surgical Research</i> , 2018, 231, 263-269.	1.6	25
141	Gastric electric stimulation for the treatment of gastroparesis. <i>Current Gastroenterology Reports</i> , 2007, 9, 286-294.	2.5	24
142	Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo Studies. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1295-1307.	3.3	24
143	Role and safety of fundoplication in esophageal disease and dysmotility syndromes. <i>Journal of Thoracic Disease</i> , 2019, 11, S1610-S1617.	1.4	24
144	Scintigraphy for Evaluation of Patients for GI Motility Disorders—The Referring Physician's Perspective. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 76-78.	4.6	23

#	ARTICLE	IF	CITATIONS
145	Cholecystectomy and Clinical Presentations of Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1062-1073.	2.3	23
146	Constipation in Patients With Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 546-558.e5.	4.4	23
147	Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1090-1097.	3.7	23
148	Surgical Outcomes After Gastric Electric Stimulator Placement for Refractory Gastroparesis. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 620-626.	1.7	22
149	Therapeutic response to domperidone in gastroparesis: A prospective study using the <sc>GCSI</sc> daily diary. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13246.	3.0	22
150	Effect of Chronic Domperidone Use on QT Interval. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 648-652.	2.2	22
151	Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit. <i>American Journal of Gastroenterology</i> , 2019, 114, 945-953.	0.4	22
152	Continuous Glucose Monitoring in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2646-2655.	2.3	21
153	Drug-drug interactions in pharmacologic management of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1528-1541.	3.0	21
154	Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). <i>American Journal of Gastroenterology</i> , 2018, 113, 39-48.	0.4	20
155	Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2231-2243.	2.3	20
156	EndoFLIP and Pyloric Dilation for Gastroparesis Symptoms Refractory to Pyloromyotomy/Pyloroplasty. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2682-2690.	2.3	20
157	Treatment of patients with diabetic gastroparesis. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-16.	0.1	20
158	Enhanced Gastric Emptying Scintigraphy to Assess Fundic Accommodation Using Intra-gastric Meal Distribution and Antral Contractility. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 138-143.	0.8	19
159	Surgical Treatment for Refractory Gastroparesis: Stimulator, Pyloric Surgery, or Both?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2204-2211.	1.7	19
160	Botulinum Toxin A Improves Symptoms of Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1396-1404.	2.3	18
161	Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2311-2320.	2.3	18
162	Gastroparesis in the 2020s: New Treatments, New Paradigms. <i>Current Gastroenterology Reports</i> , 2020, 22, 23.	2.5	18

#	ARTICLE	IF	CITATIONS
163	Subtypes of muscarinic receptors regulating gallbladder cholinergic contractions. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G1243-G1250.	3.4	17
164	Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. <i>PLoS ONE</i> , 2017, 12, e0187772.	2.5	17
165	Taste and Smell Disturbances in Patients with Gastroparesis and Gastroesophageal Reflux Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 370-377.	2.4	17
166	Características del esfínter pilórico utilizando EndoFLIP® en gastroparesia. <i>Revista De Gastroenterología De México</i> , 2018, 83, 375-384.	0.2	17
167	The impact of gastroparesis on diabetes control: Patient perceptions. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 826-829.	2.3	16
168	Emerging strategies for the treatment of gastroparesis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 817-825.	3.0	16
169	Utility of Esophageal High-Resolution Manometry in Clinical Practice: First, Do HRM. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3178-3186.	2.3	16
170	Factors that contribute to the impairment of quality of life in gastroparesis. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14087.	3.0	16
171	Methodologic considerations for studies of chronic nausea and vomiting in adults and children. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 202, 28-39.	2.8	15
172	Characterizing Abdominal Pain in Patients With Gastroparesis Into Neuropathic and Nociceptive Components. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 427-433.	2.2	15
173	Progress in Gastroparesis - A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2684-2695.e3.	4.4	15
174	Advances in the management of gastroparesis. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 283-293.	0.8	14
175	The American neurogastroenterology and motility society gastroparesis cardinal symptom index daily diary (ANMS GCSI-DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13553.	3.0	14
176	Role of Gastric Emptying in Symptoms of Gastroparesis. <i>Gastrointestinal Disorders</i> , 2019, 1, 391-402.	0.8	14
177	Transsphincteric pH Profile at the Gastroesophageal Junction. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 630-634.	4.4	13
178	Effect of Atilmotin, a Motilin Receptor Agonist, on Esophageal, Lower Esophageal Sphincter, and Gastric Pressures. <i>Digestive Diseases and Sciences</i> , 2010, 55, 300-306.	2.3	13
179	Influence of Gastric Emptying and Gut Transit Testing on Clinical Management Decisions in Suspected Gastroparesis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00084.	2.5	13
180	Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e452-e464.	4.4	13

#	ARTICLE	IF	CITATIONS
181	The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 61.	1.9	12
182	Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13720.	3.0	12
183	Body weight in patients with idiopathic gastroparesis. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13974.	3.0	12
184	Management of Delayed Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 642-646.	4.4	11
185	Training in Gastrointestinal Motility. <i>Digestive Diseases</i> , 2006, 24, 221-227.	1.9	11
186	Fatigue: A Prevalent Symptom in Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2088-2095.	2.3	11
187	Bodyweight in Patients with Idiopathic Gastroparesis: Roles of Symptoms, Caloric Intake, Physical Activity, and Body Metabolism. <i>Neurogastroenterology and Motility</i> , 2014, 26, 283-289.	3.0	11
188	Endoscopic and Surgical Treatments for Gastroparesis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 539-556.	2.2	11
189	Dual effects of PACAP on guinea pig gallbladder muscle via PACAP-preferring and VIP/PACAP-preferring receptors. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 272, G1433-G1438.	3.4	10
190	Caregiver Burden in Gastroparesis and GERD: Correlation with Disease Severity, Healthcare Utilization and Work Productivity. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3451-3462.	2.3	10
191	Gastric Electric Stimulation for Refractory Gastroparesis. <i>Journal of Clinical Outcomes Management</i> , 2019, 26, 27-38.	1.7	10
192	Malignancy-induced secondary achalasia. <i>Dysphagia</i> , 1994, 9, 292-6.	1.8	10
193	Diabetes-Related Autoantibodies in Diabetic Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1733-1737.	2.3	9
194	Effect of Bifidobacterium infantis 35624 (Align) on the Lactulose Breath Test for Small Intestinal Bacterial Overgrowth. <i>Digestive Diseases and Sciences</i> , 2018, 63, 989-995.	2.3	9
195	Post-Fundoplication Dumping Syndrome: A Frequent "Rare" Complication. <i>ACG Case Reports Journal</i> , 2018, 5, e1.	0.4	9
196	Gastric half emptying time ($T_{1/2}$) for 4h gastric emptying scintigraphy simplifies reporting but reduces detection of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2021, , e14261.	3.0	9
197	Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. <i>Xenobiotica</i> , 2009, 39, 749-756.	1.1	8
198	376 Enterra® Gastric Electrical Stimulation for Diabetic Gastroparesis: Results from a Multicenter Randomized Study. <i>Gastroenterology</i> , 2009, 136, A-61-A-62.	1.3	8

#	ARTICLE	IF	CITATIONS
199	The Gastrointestinal Motility Laboratory. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009, 19, 171-184.	1.4	8
200	Current advances in treatment of gastroparesis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1997-2008.	1.8	8
201	Multiple Rapid Swallows (MRS) Complements Single-Swallow (SS) Analysis for High-Resolution Esophageal Manometry (HREM). <i>Digestive Diseases and Sciences</i> , 2019, 64, 2206-2213.	2.3	8
202	Using gastric emptying scintigraphy to evaluate antral contractions and duodenal bolus propagation. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G203-G209.	3.4	8
203	COVID-19 infection manifesting as a severe gastroparesis flare. <i>Medicine (United States)</i> , 2021, 100, e25467.	1.0	8
204	Healthcare resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14366.	3.0	8
205	Myosin light chain phosphorylation correlates with contractile force in guinea pig gallbladder muscle. <i>Digestive Diseases and Sciences</i> , 2001, 46, 176-181.	2.3	7
206	Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with Diabetes and Symptoms of Gastroparesis. <i>Frontiers in Endocrinology</i> , 2018, 9, 32.	3.5	7
207	Towards a Fuller Assessment of Gastric Motility in Patients With Upper GI Dyspepsia: Time to Accommodate!. <i>American Journal of Gastroenterology</i> , 2019, 114, 16-18.	0.4	7
208	Factors Associated With Hospital Admissions and Readmissions in Patients With Gastroparesis Using the Nationwide Readmission Database. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 801-805.	2.2	7
209	Symptom variability throughout the day in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13740.	3.0	7
210	Which endosurgical treatment for gastroparesis: pyloromyotomy or gastric electrical stimulation?. <i>Endoscopy</i> , 2020, 52, 330-331.	1.8	6
211	Meal Eating Characteristics of Patients with Gastroparesis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3872-3880.	2.3	6
212	Effect of liquid and solid test meals on symptoms and gastric myoelectrical activity in patients with gastroparesis and functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2023, 35, e14376.	3.0	6
213	Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC-ESI-MS/MS. <i>Xenobiotica</i> , 2013, 43, 1073-1083.	1.1	5
214	Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism <i>in vitro</i> . <i>Xenobiotica</i> , 2014, 44, 792-803.	1.1	5
215	143 - Gastric Emptying Changes over Time in Gastroparesis: Comparison of Initial and 48 Week Follow up Gastric Emptying Tests in the Gastroparesis Registry of the Gastroparesis Consortium. <i>Gastroenterology</i> , 2018, 154, S-39.	1.3	5
216	Baseline Predictors of Longitudinal Changes in Symptom Severity and Quality of Life in Patients With Suspected Gastroparesis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e407-e428.	4.4	5

#	ARTICLE	IF	CITATIONS
217	Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G44-G59.	3.4	5
218	Persistent Nausea and Abdominal Pain in a Patient With Delayed Gastric Emptying. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1309-1314.	4.4	4
219	T1345 The Pathological Basis of Gastroparesis. <i>Gastroenterology</i> , 2008, 134, A-536.	1.3	4
220	DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis. <i>Journal of Biomedical Informatics</i> , 2012, 45, 316-322.	4.3	4
221	295 Pilot Study of the Safety, Feasibility, and Efficacy of Continuous Glucose Monitoring (CGM) and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG): A Multicenter, Longitudinal Trial by the NIDDK Gastroparesis Clinical Research Consortium (GPCRC). <i>Gastroenterology</i> , 2015, 148, S-64.	1.3	4
222	Su1428 Wireless Motility Capsule Gastric and Extragastric Transit and Pressure Characteristics in a Large Patient Cohort With Gastroparesis Symptoms: Relation to Scintigraphic Findings and Disease Etiology. <i>Gastroenterology</i> , 2015, 148, S-507-S-508.	1.3	4
223	Upper GI Disorders: Pathophysiology and Current Therapeutic Approaches. <i>Handbook of Experimental Pharmacology</i> , 2016, 239, 17-37.	1.8	4
224	Addition of smallâ€bowel transit scintigraphy to gastric emptying for assessment of patients with upper gastrointestinal symptoms. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13987.	3.0	4
225	Epidemiology of Gastroparesis in the United States. <i>Gastroenterology</i> , 2022, 162, 2136-2137.	1.3	4
226	Exploring genetic variability in drug therapy by selecting a minimum subset of the most informative single nucleotide polymorphisms through approximation of a markov blanket in a kernel-induced space. , 2012, , .		3
227	Slow esophageal propagation velocity: association with dysphagia for solids. <i>Neurogastroenterology and Motility</i> , 2013, 25, e44-51.	3.0	3
228	Bolus retention in hiatal hernia identified by highâ€resolution esophageal manometry with impedance. <i>Neurogastroenterology and Motility</i> , 2014, 26, 679-684.	3.0	3
229	Mo1599 Relation of Gastroparesis Symptom Severity to Gastric, Small Bowel, and Colon Transit and Contraction Profiles on Wireless Motility Capsule Testing in a Large Multicenter Cohort. <i>Gastroenterology</i> , 2016, 150, S725.	1.3	3
230	Characterizing the proximal esophageal segment in patients with symptoms of esophageal dysmotility. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13888.	3.0	3
231	Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00362.	2.5	3
232	Prevalence and clinical correlates of antinuclear antibody in patients with gastroparesis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14270.	3.0	3
233	Absorbable antibacterial envelope in the surgical management of Twiddlerâ€™s syndrome in a patient with gastric electric stimulator: a case report. <i>Digestive Medicine Research</i> , 2020, 3, 76-76.	0.2	3
234	Malignancy-induced secondary achalasia. <i>Dysphagia</i> , 1993, 8, 292-6.	1.8	3

#	ARTICLE	IF	CITATIONS
235	Characterizing reflux on high resolution esophageal manometry with impedance. BMC Gastroenterology, 2022, 22, 112.	2.0	3
236	The Gastrointestinal Motility Laboratory. Gastroenterology Clinics of North America, 2007, 36, 515-529.	2.2	2
237	Improving Our Understanding of Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, xv-xvi.	2.2	2
238	Mo1581 Impaired Quality of Life in Gastroparesis: Relationships to Symptoms of Gastroparesis. Gastroenterology, 2016, 150, S718.	1.3	2
239	Gastric Motility. , 2020, , 598-612.		2
240	Vascular pressure bands on high-resolution esophageal manometry with impedance studies. Ecological Management and Restoration, 2020, 33, .	0.4	2
241	Distal Esophageal Impedance Measured by High-resolution Esophageal Manometry With Impedance Suggests the Presence of Barrett's Esophagus. Journal of Neurogastroenterology and Motility, 2020, 26, 344-351.	2.4	2
242	Rheumatologic disorders in patients undergoing esophageal manometry: prevalence, symptom characteristics, and manometric findings. Ecological Management and Restoration, 2021, 34, .	0.4	2
243	Normal Gastrointestinal Tract Physiology. , 2022, , 3-28.		2
244	A cross-sectional study describing peripheral neuropathy in patients with symptoms of gastroparesis: associations with etiology, gastrointestinal symptoms, and gastric emptying. BMC Gastroenterology, 2022, 22, .	2.0	2
245	New advances in the diagnosis and management of nausea and vomiting. The Case Manager, 2002, 13, 83-87.	0.2	1
246	Gastric Emptying Studies. , 2018, , 309-315.		1
247	Modern Approaches for Evaluation and Treatment of Gastrointestinal Motility Disorders. Gastroenterology Clinics of North America, 2020, 49, xv-xvi.	2.2	1
248	Prokinetic agents for gastroparesis. , 2021, , 323-339.		1
249	Detection and characteristics of rumination syndrome in patients presenting for gastric symptom evaluation. Neurogastroenterology and Motility, 2021, 33, e14103.	3.0	1
250	Impact of patient position on esophageal motility disorders using high-resolution esophageal manometry with impedance (HREMI): supine versus upright swallows. Esophagus, 2021, 18, 880-888.	1.9	1
251	Gastroparesis. , 2020, , 720-730.		1
252	Gastric Emptying Scintigraphy Results in the ROME III Subgroup Classifications for Functional Gastrointestinal Disorders. American Journal of Gastroenterology, 2007, 102, S507.	0.4	1

#	ARTICLE	IF	CITATIONS
253	Abdominal pain in gastroparesis. , 2022, , 173-188.		1
254	S0351â€fCharacterizing Reflux on High Resolution Esophageal Manometry With Impedance. American Journal of Gastroenterology, 2020, 115, S173-S173.	0.4	1
255	Hiatal hernias associated with acid reflux: size larger than 2â€cm matters. Ecological Management and Restoration, 2022, , .	0.4	1
256	Nonulcer dyspepsia. Current Treatment Options in Gastroenterology, 1998, 1, 15-19.	0.8	0
257	Disorders of gastric emptying. , 0, , 903-935.		0
258	Gastroparesis. Frontiers of Gastrointestinal Research, 2014, , 25-37.	0.1	0
259	Gastroparesis, Postprandial Distress. , 2018, , 269-281.		0
260	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 999-1000.	4.4	0
261	Gastroparesis. , 2020, , 265-280.		0
262	Evaluating response in gastroparesis: Patient reported outcome measures and survey instruments. , 2021, , 451-460.		0
263	Studies from the NIH Gastroparesis Clinical Research Consortium: Towards improving our understanding and treatment of gastroparesis. , 2021, , 443-449.		0
264	Abdominal pain in gastroparesis: Prevalence, potential causes and management. , 2021, , 361-375.		0
265	Gastric emptying scintigraphy. , 2021, , 125-142.		0
266	Editorial: on the road towards treatment of gastroparesisâ€”accelerating, but do we get closer? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 185-186.	3.7	0
267	Pain Management for Gastroparesis. , 2012, , 289-302.		0
268	Minimally Invasive Fundoplication is Safe and Effective in Patients with Severe Esophageal Hypomotility. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2016, 11, 396-399.	0.9	0
269	Future Directions in Understanding Nausea and Vomiting. , 2017, , 211-217.		0
270	Idiopathic Gastroparesis. , 2019, , 75-98.		0